Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

Journal of Clinical Oncology

Volumn 23, Issue 29, 2005, Pages 7265-7277

  Gianni, Luca ^a   Zambetti, Milvia ^a   Clark, Kim ^a   Baker, Joffre ^a   Cronin, Maureen ^a   Wu, Jenny ^a   Mariani, Gabriella ^a   Rodriguez, Jaime ^a   Carcangiu, Marialuisa ^a   Watson, Drew ^a   Valagussa, Pinuccia ^a   Rouzier, Roman ^a   Symmans, W Fraser ^a   Ross, Jeffrey S ^a   Hortobagyi, Gabriel N ^a   Pusztai, Lajos ^a   Shak, Steven ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PARAFFIN; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR VOLUME; BREAST; BREAST TUMOR; CANCER STAGING; GENETICS; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PREDICTION AND FORECASTING; REMISSION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOPSY, NEEDLE; BREAST; BREAST NEOPLASMS; DOXORUBICIN; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PACLITAXEL; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 28044472321     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.0818     Document Type: Article

References (44)

1. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
2. Bonadonna G, Valagussa P, Brambilla C, et al: Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol 16:93-100, 1998
3. Smith IC, Heys SD, Hutcheon AW, et al: Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 20:1456-1466, 2002
4. Kaufmann M, von Minckwitz G, Smith R, et al: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Review and recommendations. J Clin Oncol 21:2600-2608, 2003
5. Rouzier R, Wagner P, Morandi P, et al: Gene expression profiling of primary breast cancer. Curr Oncol Rep 7:38-44, 2005
6. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874, 2001
7. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
8. Chang J, Powles TJ, Allred DC, et al: Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17:3058-3063, 1999
9. Sotiriou C, Powles TJ, Dowsett M, et al: Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 4:R3, 2002
10. Assersohn L, Gangi L, Zhao Y, et al: The feasibility of using fine needle aspiration from primary breast cancers for cDNA microarray analyses. Clin Cancer Res 8:794-801, 2002
11. Ayers M, Symmans WF, Stec J, et al: Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22:2284-2293, 2004
12. Ellis M, Davis N, Coop A, et al: Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. Clin Cancer Res 8:1155-1166, 2002
13. Karsten SL, Van Deerlin VM, Sabatti C, et al: An evaluation of tyramide signal amplification and archived fixed and frozen tissue in microarray gene expression analysis. Nucleic Acids Res 30:E4, 2002
14. Ramaswamy S, Golub TR: DNA microarrays in clinical oncology. J Clin Oncol 20:1932-1941, 2002
15. Cronin M, Pho M, Dutta D, et al: Measurement of gene expression in archival paraffin-embedded tissues: Development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 164:35-42, 2004
16. Specht K, Richter T, Muller U, et al: Quantitative gene expression analysis in micro-dissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 158: 419-429, 2001
17. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
18. McShane LM, Radmacher MD, Simon R: Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data. Bioinformatics 18:1462-1469, 2002
19. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
20. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415(6871):530-6.
21. Chang JC, Wooten EC, Tsimelzon A, et al: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362-369, 2003
22. Duran GE, Wang YC, Francisco B, et al: Identification of genes associated with non-MDR1 taxane resistance in human ovarian carcinoma cell lines by microarray analysis. Am Assoc Cancer Res, 2003 (abstr 5760)
23. Lamendola DE, Duan Z, Yusuf RZ, et al: Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res 63:2200-2205, 2003
24. Duan Z, Feller AJ, Pensen RT, et al: Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 5:3445-3453, 1999
25. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer, I: The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403-410, 1991
26. Symmans WF, Ayers M, Clark EA, et al: Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 97:2960-2971, 2003
27. Hosmer DW, Lemeshow S: Applied Logistic Regression. New York, NY, Wiley, 1989
28. B. J. T. Morgan: Analysis of Quantal Response Data. New York, NY, Chapman and Hall, 1992
29. Harrel FE Jr: Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY, Springer-Verlag, 2001
30. Efron B, Tibshirani R: An Introduction to the Bootstrap. New York, NY, Chapman and Hall, 1993
31. Somers RH: A new asymmetric measure of association for ordinal variables. Am Sociol Rev 27:799-811, 1962
32. Nagelkerke NJD: A note on a general definition of the coefficient of determination. Biometrika 78:691-692, 1991
33. Efron B: Estimating the error rate of a prediction rule: Improvement on cross-validation. J Am Stat Assoc 78:316-331, 1983
34. Kuo WP, Jenssen TK, Butte AJ, et al: Analysis of matched mRNA measurements from two different microarray technologies. Bioinformatics 18:405-412, 2002
35. Yuen T, Wurmbach E, Pfeffer RL, et al: Accuracy and calibration of commercial oligonucleotide and custom cDNA microarrays. Nucleic Acids Res 30:e48, 2002
36. Ioannidis JP: Microarrays and molecular research: Noise discovery? Lancet 365:454-455, 2005
37. Lippman ME, Allegra JC, Thompson EB, et al: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298:1223-1228, 1978
38. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999
39. Colleoni M, Minchella I, Mazzarol G, et al: Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 11:1057-1059, 2000
40. Gianni L, Baselga J, Eiermann W, et al: First report of the European Cooperative Trial in operable breast cancer (ECTO): Effects of primary systemic therapy (PST) on local-regional disease. Proc Am Soc Clin Oncol, 2002 (abstr 132)
41. Penson RT, Oliva E, Skates SJ, et al: Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: A study in serial samples. Gynecol Oncol 93:98-106, 2004
42. Wu H, Hait WN, Yang JM: Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 63: 1515-1519, 2003
43. Burger H, Foekens JA, Look MP, et al: RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: Correlation with chemotherapeutic response. Clin Cancer Res 9:827-836, 2003
44. Faneyte IF, Kristel PM, van de Vijver MJ: Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. Anticancer Res 24:2931-2939, 2004